|
|
Article: Neurogen Gets Back All Rights To CRF Program From Aventis.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Neurogen Corp. is regaining full rights to its corticotrophin releasing factor-based drugs through the dissolution of its partnership with Aventis SA, now part of the new Sanofi-Aventis entity.
Since the merger has been in the works for some time, the move might have been expected for a company in Neurogen's position, but in any case, the Branford, Conn.-based business is eyeing its regained rights as a plus.
"In terms of mergers, it's always difficult to predict what's going to happen," Neurogen President and CEO William Koster told BioWorld Today. "There's no way we could have said that we knew in an absolute sense what ...
Related newspaper, magazine, and journal articles:
|
|
Article: Neurogen Suffer Setback With Pfizer, Enters Deal With ...
BIOWORLD Today;
December 21, 2001 ;
700+ words
... ... Branford, Conn.-based Neurogen. "Even though the ... date, Pfizer has paid Neurogen $60 million in research ... development costs. (See BioWorld Today, June 19, 1999; Nov ... preliminary, Jim Cassella, Neurogen's vice president of ...
|
|